Treace Medical Concepts Posts Q2 Revenue of $45.4M, Beats EPS Estimate as Year-to-Date Cash Usage Falls $3.6 Million

Treace Medical Concepts (NasdaqGS: TMCI) reported Q2 2026 revenue of $45.4 million on Friday, August 7, 2026 — down from $47.4 million in Q2 2025, but above the analyst consensus estimate of $44.02 million, according to the company's August 7 news release via GlobeNewswire.

TMCI posted a net loss of $0.28 per share against a consensus estimate of $(0.30), the second consecutive quarter the company has topped that line. In Q1 2026, it reported EPS of $(0.28) against a consensus of $(0.31), per the research brief.

Net loss for the quarter came in at $(15.9) million. Adjusted EBITDA was $(3.5) million. Cash, cash equivalents, and marketable securities totaled $45.6 million as of June 30, 2026, per the August 7 release.

Treace reduced year-to-date cash usage by 57%, or $3.6 million, compared to the same period in 2025, according to the August 7 news release.

On the product side, Treace initiated a limited market release of its SuperBite™ Compression Screw System and completed the first surgical case using the HyperPlate™ XM Dynamic Compression Locking Implant System, per the August 7 release. The company also flagged planned 2026 launches of Lapiplasty Lightning and IntelliGuide PSI systems as part of its effort to expand its bunion surgery portfolio.

Full-year 2025 revenue was $212.69 million, up from $209.36 million the prior year, per the research brief. For 2026, the company's own guidance anticipates flat to negative 6% revenue, a range that frames the slight year-over-year quarterly decline as consistent with internal expectations rather than a surprise deterioration.

Analyst sentiment on TMCI sits at a consensus "Hold" across five analysts, with a 12-month price target of $4.00, per the research brief. Truist Financial raised its price objective from $2.00 to $4.00 on July 16, 2026, while maintaining that Hold rating. The stock opened at $4.78 on August 5; its 50-day simple moving average stands at $4.13 and its 200-day at $2.72. The 1-year range runs from a low of $1.17 to a high of $7.78.

Treace hosted a conference call at 8:00 a.m. ET on August 7, 2026 to discuss the results. The next concrete catalysts on the calendar, per the release, are the commercial rollouts of Lapiplasty Lightning and IntelliGuide PSI — both targeted for 2026, with no specific dates disclosed.